Abstract
A number of factors limit the therapeutic application of neurotrophin proteins, such as nerve growth factor (NGF) and brain-derived growth factor (BDNF), for Alzheimers and other neurodegenerative diseases. These factors include unfavorable pharmacological properties typical of proteins and the pleiotropic effects mediated by protein-ligand interactions with p75NTR, Trk, and sortilin neurotrophin receptors. Targeted modulation of p75NTR provides a strategy for preventing degeneration without promoting TrkA-mediated deleterious effects, and targeted activation of TrkB might achieve more favorable neurotrophic effects than those achieved by concomitant activation of p75NTR and TrkB. The discovery of small molecules functioning as ligands at specific neurotrophin receptors has made possible for the first time approaches for modulating selected components of neurotrophin signaling processes for the purpose of modulating underlying Alzheimers disease mechanisms.
Keywords: TrkA interaction, AKT signaling, BDNF polymorphism, neurotrophic effect, NGF promotion
Current Alzheimer Research
Title: Small Molecule Neurotrophin Receptor Ligands: Novel Strategies for Targeting Alzheimers Disease Mechanisms
Volume: 4 Issue: 5
Author(s): Frank M. Longo, Tao Yang, Juliet K. Knowles, Youmei Xie, Laura A. Moore and Stephen M. Massa
Affiliation:
Keywords: TrkA interaction, AKT signaling, BDNF polymorphism, neurotrophic effect, NGF promotion
Abstract: A number of factors limit the therapeutic application of neurotrophin proteins, such as nerve growth factor (NGF) and brain-derived growth factor (BDNF), for Alzheimers and other neurodegenerative diseases. These factors include unfavorable pharmacological properties typical of proteins and the pleiotropic effects mediated by protein-ligand interactions with p75NTR, Trk, and sortilin neurotrophin receptors. Targeted modulation of p75NTR provides a strategy for preventing degeneration without promoting TrkA-mediated deleterious effects, and targeted activation of TrkB might achieve more favorable neurotrophic effects than those achieved by concomitant activation of p75NTR and TrkB. The discovery of small molecules functioning as ligands at specific neurotrophin receptors has made possible for the first time approaches for modulating selected components of neurotrophin signaling processes for the purpose of modulating underlying Alzheimers disease mechanisms.
Export Options
About this article
Cite this article as:
Longo M. Frank, Yang Tao, Knowles K. Juliet, Xie Youmei, Moore A. Laura and Massa M. Stephen, Small Molecule Neurotrophin Receptor Ligands: Novel Strategies for Targeting Alzheimers Disease Mechanisms, Current Alzheimer Research 2007; 4 (5) . https://dx.doi.org/10.2174/156720507783018316
DOI https://dx.doi.org/10.2174/156720507783018316 |
Print ISSN 1567-2050 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5828 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Author Index To Volume 6
Central Nervous System Agents in Medicinal Chemistry Modulation of Retinal Arteriolar Central Reflection by APOE Genotype
Current Alzheimer Research Isolation of Sinapic Acid from Habenaria intermedia D. Don: A New Chemical Marker for the Identification of Adulteration and Substitution
Current Traditional Medicine Stress as a Pathophysiological Factor in Functional Somatic Syndromes
Current Psychiatry Reviews Oral Inflammation and Bacteremia: Implications for Chronic and Acute Systemic Diseases Involving Major Organs
Cardiovascular & Hematological Disorders-Drug Targets Cyclooxygenase and Neuroinflammation in Parkinsons Disease Neurodegeneration
Current Neuropharmacology Proteins of the Esterase Family: Patents for Some Proteins in Search of Metabolic Functions
Recent Patents on Biomarkers Resistance of Cancer Cells to Targeted Therapies Through the Activation of Compensating Signaling Loops
Current Signal Transduction Therapy The Impacts of Some Sedative Drugs on α -Glycosidase, Acetylcholinesterase and Butyrylcholinesterase Enzymes-potential Drugs for Some Metabolic Diseases
Letters in Drug Design & Discovery Increase Signaling of Wnt/β-Catenin Pathway and Presence of Apoptosis in Cerebellum of Kindled Rats
CNS & Neurological Disorders - Drug Targets Clinical Applicability of Sequence Variations in Genes Related to Drug Metabolism
Current Drug Metabolism Highlighting the Role of Cognitive and Brain Reserve in the Substance use Disorder Field
Current Neuropharmacology Strategies for Targeting Lentiviral Vectors
Current Gene Therapy Viral Envelope Membrane: A Special Entry Pathway and a Promising Drug Target
Current Medicinal Chemistry Cardiovascular and Renovascular Implications of COX-2 Inhibition
Current Pharmaceutical Design Editorial [Hot topic:VIP and PACAP: Novel Approaches to Brain Functions and Neuroprotection (Executive Guest Editors: Seiji Shioda and Illana Gozes)]
Current Pharmaceutical Design Commentary: (Research Highlights: “MiRNAcles” in Brain)
CNS & Neurological Disorders - Drug Targets Sphingolipid Modulation: A Strategy for Cancer Therapy
Anti-Cancer Agents in Medicinal Chemistry Nasal <i>In-situ</i> Gel: An Approach to Enhance Therapeutic Benefits of the Drug
Drug Delivery Letters Cellular and Molecular Mechanisms of Low Cardiac Output Syndrome after Pediatric Cardiac Surgery
Current Vascular Pharmacology